معرفی
Dr. Chris Boyd is a Reader (equivalent to Associate Professor) at the University of Edinburgh's Institute of Genetics and Cancer, where he leads the Chris Boyd Research Group within the Centre for Genomic and Experimental Medicine. His work focuses on developing pulmonary gene therapy approaches to treat cystic fibrosis and other genetic diseases, with significant contributions to the UK CF Gene Therapy Consortium formed in 2001 by research groups in London, Oxford, and Edinburgh.
Dr. Boyd's research program has two main fronts in cystic fibrosis gene therapy. In Wave 1, his team developed and tested a nonviral product (pGM169/GL67A) in a Phase IIb clinical trial that demonstrated the ability to arrest lung function decline. In Wave 2, he is developing a more efficient lentiviral vector (rSIV.F/HN) for delivering transgenes to the lung, with his group assessing safety and monitoring CFTR expression from transduced cells. His expertise spans translational medicine, gene therapy, synthetic biology, recombinant DNA technology, airway cell biology, immunohistochemistry, and genotoxicity.
His publication record shows consistent progression from preclinical development through to human trials, with recent work (2022-2024) focusing on lentiviral approaches and biomarker development for monitoring disease progression. This reflects a maturing research program moving toward clinical application.
Dr. Boyd collaborates extensively with researchers across the UK, including Dr. Gerry McLachlan and Dr. David Collie at the University of Edinburgh, Prof. Eric Alton and Prof. Jane Davies at Imperial College London, and colleagues at the University of Oxford and University of Bristol. His research is supported by the Cystic Fibrosis Trust, Imperial College of Science Technology and Medicine, Just Gene Therapy, and various charities.
